James G. Dickinson

The center seems to have heightened its censorship and nondisclosure on LASIK devices.

Congress sets initiatives in motion to reverse the Supreme Court’s decision in Riegel v. Medtronic.

The answer to how much money the agency spent on litigation in two crucial cases may be elusive.

  ...

After some prodding from Congress, the FDA commissioner admits that the agency needs much more money than was originally allotted.

Several congressmen inquire about FDA’s timing of a crucial civil money penalties case.

The agency’s plan for better cooperation with its counterpart agencies around the world has started to come to fruition.

FDA’s annual report of significant legal decisions seems to be incomplete without a mention of Utah Medical.